42.50 0.00 (0.00%)
After hours: 4:16PM EDT
|Bid||42.60 x 900|
|Ask||42.61 x 900|
|Day's range||42.47 - 43.20|
|52-week range||31.56 - 43.66|
|Beta (3Y monthly)||0.70|
|PE ratio (TTM)||42.93|
|Earnings date||22 Oct 2019 - 28 Oct 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||48.14|
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and -0.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.
In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices
Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.
The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.